 |
 |
|
Home |
Current Issue |
Past Issues |
In the Clinic |
ACP Journal Club |
CME |
Collections |
Audio/Video |
Mobile |
Subscribe |
Tools |
Help |
ACP Online
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Summaries for Patients are a service provided by Annals to help patients better understand the complicated and often mystifying language of modern medicine.
SUMMARIES FOR PATIENTS
Sildenafil (Viagra) May Help Improve Control of Pulmonary Hypertension
2 April 2002 | Volume 136 Issue 7 | Page I35
Summaries for Patients are presented for informational purposes only. These summaries are not a substitute for advice from your own medical provider. If you have questions about this material, or need medical advice about your own health or situation, please contact your physician. The summaries may be reproduced for not-for-profit educational purposes only. Any other uses must be approved by the American College of Physicians-American Society of Internal Medicine.
The summary below is from the full report titled "Combination Therapy with Oral Sildenafil and Inhaled Iloprost for Severe Pulmonary Hypertension." It is in the 2 April 2002 issue of Annals of Internal Medicine (volume 136, pages 515-522). The authors are HA Ghofrani, R Wiedemann, F Rose, H Olschewski, RT Schermuly, N Weissmann, W Seeger, and F Grimminger. The summaries may be reproduced for not-for-profit educational purposes only. Any other uses must be approved by the American College of Physicians-American Society of Internal Medicine.
What is the problem and what is known about it so far?
Some diseases can narrow the blood vessels in the lungs, which leads to high blood pressure in the lungs (pulmonary hypertension) even when blood pressure in the rest of the body is normal. Pulmonary hypertension is a highly fatal disorder since the strain of pumping blood through narrowed vessels often leads to failure of the heart muscle. When the heart muscle fails, the lungs cannot supply enough oxygen to meet the body's needs. Treatments for this disorder widen the damaged blood vessels in the lung and make it easier for the heart to pump blood through the lungs. One such drug (epoprostenol) is effective only if given intravenously through a small plastic tube that must remain in the vein permanently. Another treatment involves continuous inhalation of a gas (nitric oxide) that also widens blood vessels in the lungs. A newer approach has been an inhaled mist form of epoprostenol called iloprost. Because each mist treatment lasts only about 60 minutes, up to 12 treatments each day are required. Each of these treatments has its drawbacks. Recently, researchers learned that a drug used for erectile dysfunction, sildenafil (Viagra), can enhance and prolong the actions of both iloprost and nitric oxide.
Why did the researchers do this particular study?
To see whether sildenafil alone and combined with other treatments was an effective treatment for pulmonary hypertension.
Who was studied?
30 patients with severe pulmonary hypertension; 11 of these patients had previously received iloprost.
How was the study done?
All patients received nitric oxide inhalation alone and were then randomly assigned to one of four treatment groups: 1) low-dose sildenafil, 2) low-dose sildenafil followed by inhaled iloprost, 3) high-dose sildenafil, or 4) high-dose sildenafil followed by inhaled iloprost. The researchers measured blood flow and blood pressure in the lung vessels at intervals for up to 3 hours.
What did the researchers find?
High-dose sildenafil followed by inhaled iloprost was the most effective treatment for pulmonary hypertension. The next most effective treatment was low-dose sildenafil plus inhaled iloprost, followed by either iloprost alone or high-dose sildenafil alone (both were about equally effective). Least effective was either low-dose sildenafil alone or nitric oxide inhalation alone. No patients experienced serious side effects.
What were the limitations of the study?
The authors could not measure the effect of the treatment on some causes of pulmonary hypertension because they excluded patients with these diseases from the study. In addition, the study included a relatively small number of patients and had a short observation period.
What are the implications of the study?
When combined with standard treatments for pulmonary hypertension, sildenafil may significantly improve control of this fatal disease. Because experience with this treatment is limited, it is too early to make firm recommendations for treatment.
Related articles in Annals:
This article has been cited by other articles:
|
|
 |
|
  J. Suntharalingam, C. M. Treacy, N. J. Doughty, K. Goldsmith, E. Soon, M. R. Toshner, K. K. Sheares, R. Hughes, N. W. Morrell, and J. Pepke-Zaba Long-term Use of Sildenafil in Inoperable Chronic Thromboembolic Pulmonary Hypertension Chest, August 1, 2008; 134(2): 229 - 236. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. R. Wilkins, J. Wharton, F. Grimminger, and H. A. Ghofrani Phosphodiesterase inhibitors for the treatment of pulmonary hypertension Eur. Respir. J., July 1, 2008; 32(1): 198 - 209. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Gomberg-Maitland and H. Olschewski Prostacyclin therapies for the treatment of pulmonary arterial hypertension Eur. Respir. J., April 1, 2008; 31(4): 891 - 901. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 National Pulmonary Hypertension Centres of the UK Consensus statement on the management of pulmonary hypertension in clinical practice in the UK and Ireland Heart, March 1, 2008; 94(Suppl_1): i1 - i41. [Full Text] [PDF]
|
|
|
|
 |
|
 National Pulmonary Hypertension Centres of the UK Consensus statement on the management of pulmonary hypertension in clinical practice in the UK and Ireland Thorax, March 1, 2008; 63(Suppl_2): ii1 - ii41. [Full Text] [PDF]
|
|
|
|
|
|
F. Reichenberger, R. Voswinckel, B. Enke, M. Rutsch, E. El Fechtali, T. Schmehl, H. Olschewski, R. Schermuly, N. Weissmann, H. A. Ghofrani, et al. Long-term treatment with sildenafil in chronic thromboembolic pulmonary hypertension Eur. Respir. J., November 1, 2007; 30(5): 922 - 927. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Pizanis, V. Milekhin, K. Tsagakis, I. Aleksic, M. Kamler, and H. Jakob PDE-5 inhibitor donor intravenous preconditioning is superior to supplementation in standard preservation solution in experimental lung transplantation Eur. J. Cardiothorac. Surg., July 1, 2007; 32(1): 42 - 47. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. T.-J. Gan, S. Holverda, J. T. Marcus, W. J. Paulus, K. M. Marques, J. G.F. Bronzwaer, J. W. Twisk, A. Boonstra, P. E. Postmus, and A. Vonk-Noordegraaf Right Ventricular Diastolic Dysfunction and the Acute Effects of Sildenafil in Pulmonary Hypertension Patients Chest, July 1, 2007; 132(1): 11 - 17. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Suntharalingam, R. D Machado, L. D Sharples, M. R Toshner, K. K Sheares, R. J Hughes, D. P Jenkins, R. C Trembath, N. W Morrell, and J. Pepke-Zaba Demographic features, BMPR2 status and outcomes in distal chronic thromboembolic pulmonary hypertension Thorax, July 1, 2007; 62(7): 617 - 622. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. B. Badesch, S. H. Abman, G. Simonneau, L. J. Rubin, and V. V. McLaughlin Medical Therapy for Pulmonary Arterial Hypertension: Updated ACCP Evidence-Based Clinical Practice Guidelines Chest, June 1, 2007; 131(6): 1917 - 1928. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. T. Schermuly, S. S. Pullamsetti, G. Kwapiszewska, R. Dumitrascu, X. Tian, N. Weissmann, H. A. Ghofrani, C. Kaulen, T. Dunkern, C. Schudt, et al. Phosphodiesterase 1 Upregulation in Pulmonary Arterial Hypertension: Target for Reverse-Remodeling Therapy Circulation, May 1, 2007; 115(17): 2331 - 2339. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. T. Klodell Jr, T. E. Morey, E. B. Lobato, J. M. Aranda Jr, E. D. Staples, R. S. Schofield, P. J. Hess, T. D. Martin, and T. M. Beaver Effect of Sildenafil on Pulmonary Artery Pressure, Systemic Pressure, and Nitric Oxide Utilization in Patients With Left Ventricular Assist Devices Ann. Thorac. Surg., January 1, 2007; 83(1): 68 - 71. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Mereles, N. Ehlken, S. Kreuscher, S. Ghofrani, M. M. Hoeper, M. Halank, F. J. Meyer, G. Karger, J. Buss, J. Juenger, et al. Exercise and Respiratory Training Improve Exercise Capacity and Quality of Life in Patients With Severe Chronic Pulmonary Hypertension Circulation, October 3, 2006; 114(14): 1482 - 1489. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. A. Ghofrani, R. Voswinckel, F. Reichenberger, N. Weissmann, R. T. Schermuly, W. Seeger, and F. Grimminger Hypoxia- and non-hypoxia-related pulmonary hypertension - Established and new therapies Cardiovasc Res, October 1, 2006; 72(1): 30 - 40. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Bresser, J. Pepke-Zaba, X. Jais, M. Humbert, and M. M. Hoeper Medical Therapies for Chronic Thromboembolic Pulmonary Hypertension: An Evolving Treatment Paradigm Proceedings of the ATS, September 1, 2006; 3(7): 594 - 600. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Reichenberger, R. Voswinckel, E. Steveling, B. Enke, A. Kreckel, H. Olschewski, F. Grimminger, W. Seeger, and H. A. Ghofrani Sildenafil treatment for portopulmonary hypertension Eur. Respir. J., September 1, 2006; 28(3): 563 - 567. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z.-K. Dai, M.-S. Tan, C.-Y. Chai, S.-H. Chou, P.-C. Lin, J.-L. Yeh, A. Y. Jeng, C.-I Chang, I.-J. Chen, and J.-R. Wu Effects of Sildenafil on Pulmonary Hypertension and Levels of ET-1, eNOS, and cGMP in Aorta-Banded Rats. Experimental Biology and Medicine, June 1, 2006; 231(6): 942 - 947. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. R. Hsu, K. E. Barnholt, N. K. Grundmann, J. H. Lin, S. W. McCallum, and A. L. Friedlander Sildenafil improves cardiac output and exercise performance during acute hypoxia, but not normoxia J Appl Physiol, June 1, 2006; 100(6): 2031 - 2040. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. B. Lobato, T. Beaver, J. Muehlschlegel, D. S. Kirby, C. Klodell, and A. Sidi Treatment with phosphodiesterase inhibitors type III and V: milrinone and sildenafil is an effective combination during thromboxane-induced acute pulmonary hypertension Br. J. Anaesth., March 1, 2006; 96(3): 317 - 322. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. J. Rubin Pulmonary arterial hypertension. Proceedings of the ATS, January 1, 2006; 3(1): 111 - 115. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Kramm, B. Eberle, S. Guth, and E. Mayer Inhaled iloprost to control residual pulmonary hypertension following pulmonary endarterectomy Eur. J. Cardiothorac. Surg., December 1, 2005; 28(6): 882 - 888. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Galie, H. A. Ghofrani, A. Torbicki, R. J. Barst, L. J. Rubin, D. Badesch, T. Fleming, T. Parpia, G. Burgess, A. Branzi, et al. Sildenafil Citrate Therapy for Pulmonary Arterial Hypertension N. Engl. J. Med., November 17, 2005; 353(20): 2148 - 2157. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Fries, K. Shariat, H. von Wilmowsky, and M. Bohm Sildenafil in the Treatment of Raynaud's Phenomenon Resistant to Vasodilatory Therapy Circulation, November 8, 2005; 112(19): 2980 - 2985. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. M. Hoeper, T. Kramm, H. Wilkens, C. Schulze, H. J. Schafers, T. Welte, and E. Mayer Bosentan Therapy for Inoperable Chronic Thromboembolic Pulmonary Hypertension Chest, October 1, 2005; 128(4): 2363 - 2367. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. H. Leuchte, M. Holzapfel, R. A. Baumgartner, C. Neurohr, M. Vogeser, and J. Behr Characterization of Brain Natriuretic Peptide in Long-term Follow-up of Pulmonary Arterial Hypertension Chest, October 1, 2005; 128(4): 2368 - 2374. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. A. Ghofrani, W. Seeger, and F. Grimminger Imatinib for the treatment of pulmonary arterial hypertension. N. Engl. J. Med., September 29, 2005; 353(13): 1412 - 1413. [Full Text] [PDF]
|
|
|
|
|
|
G. Piazza and S. Z. Goldhaber The Acutely Decompensated Right Ventricle: Pathways for Diagnosis and Management Chest, September 1, 2005; 128(3): 1836 - 1852. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. J. Rubin and D. B. Badesch Evaluation and Management of the Patient with Pulmonary Arterial Hypertension Ann Intern Med, August 16, 2005; 143(4): 282 - 292. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. E Baker and R. H. Hockman Inhaled Iloprost in Pulmonary Arterial Hypertension Ann. Pharmacother., July 1, 2005; 39(7): 1265 - 1274. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. A. Dias-Junior, D. C. Souza-Costa, T. Zerbini, J. B. T. da Rocha, R. F. Gerlach, and J. E. Tanus-Santos The Effect of Sildenafil on Pulmonary Embolism-Induced Oxidative Stress and Pulmonary Hypertension Anesth. Analg., July 1, 2005; 101(1): 115 - 120. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Humpl, J. T. Reyes, H. Holtby, D. Stephens, and I. Adatia Beneficial Effect of Oral Sildenafil Therapy on Childhood Pulmonary Arterial Hypertension: Twelve-Month Clinical Trial of a Single-Drug, Open-Label, Pilot Study Circulation, June 21, 2005; 111(24): 3274 - 3280. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Ng, S. J. Finney, R. Shulman, G. J. Bellingan, M. Singer, and P. A. Glynne Treatment of pulmonary hypertension in the general adult intensive care unit: a role for oral sildenafil? Br. J. Anaesth., June 1, 2005; 94(6): 774 - 777. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. J Lee, T. B Chiao, and M. P Tsang Sildenafil for Pulmonary Hypertension Ann. Pharmacother., May 1, 2005; 39(5): 869 - 884. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. L. Trachte, E. B. Lobato, F. Urdaneta, P. J. Hess, C. T. Klodell, T. D. Martin, E. D. Staples, and T. M. Beaver Oral Sildenafil Reduces Pulmonary Hypertension After Cardiac Surgery Ann. Thorac. Surg., January 1, 2005; 79(1): 194 - 197. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M.M. Hoeper, C. Faulenbach, H. Golpon, J. Winkler, T. Welte, and J. Niedermeyer Combination therapy with bosentan and sildenafil in idiopathic pulmonary arterial hypertension Eur. Respir. J., December 1, 2004; 24(6): 1007 - 1010. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. M. Lowson Alternatives to nitric oxide Br. Med. Bull., November 5, 2004; 70(1): 119 - 131. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. A. Palmieri, F. Affuso, S. Fazio, and D. Lembo Tadalafil in Primary Pulmonary Arterial Hypertension Ann Intern Med, November 2, 2004; 141(9): 743 - 744. [Full Text] [PDF]
|
|
|
|
 |
|
 H. A. Ghofrani, R. Voswinckel, F. Reichenberger, H. Olschewski, P. Haredza, B. Karadas, R. T. Schermuly, N. Weissmann, W. Seeger, and F. Grimminger Differences in hemodynamic and oxygenation responses to three different phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension: A randomized prospective study J. Am. Coll. Cardiol., October 6, 2004; 44(7): 1488 - 1496. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Humbert, O. Sitbon, and G. Simonneau Treatment of Pulmonary Arterial Hypertension N. Engl. J. Med., September 30, 2004; 351(14): 1425 - 1436. [Full Text] [PDF]
|
|
|
|
|
|
H. A. Ghofrani, F. Reichenberger, M. G. Kohstall, E. H. Mrosek, T. Seeger, H. Olschewski, W. Seeger, and F. Grimminger Sildenafil Increased Exercise Capacity during Hypoxia at Low Altitudes and at Mount Everest Base Camp: A Randomized, Double-Blind, Placebo-Controlled Crossover Trial Ann Intern Med, August 3, 2004; 141(3): 169 - 177. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. B. Badesch, S. H. Abman, G. S. Ahearn, R. J. Barst, D. C. McCrory, G. Simonneau, and V. V. McLaughlin Medical Therapy For Pulmonary Arterial Hypertension: ACCP Evidence-Based Clinical Practice Guidelines Chest, July 1, 2004; 126(1_suppl): 35S - 62S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. A. Ghofrani, J. Pepke-Zaba, J. A. Barbera, R. Channick, A. M. Keogh, M. A. Gomez-Sanchez, M. Kneussl, and F. Grimminger Nitric oxide pathway and phosphodiesterase inhibitors in pulmonary arterial hypertension J. Am. Coll. Cardiol., June 16, 2004; 43(12_Suppl_S): 68S - 72S. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Confalonieri, V. Antonaglia, U. Lucangelo, A. Gullo, M. Humbert, and G. Simonneau Sildenafil in Pulmonary Arterial Hypertension Am. J. Respir. Crit. Care Med., June 1, 2004; 169(11): 1256 - 1257. [Full Text]
|
|
|
|
 |
|
 C. Napoli and J. Loscalzo Nitric Oxide and Other Novel Therapies for Pulmonary Hypertension Journal of Cardiovascular Pharmacology and Therapeutics, March 1, 2004; 9(1): 1 - 8. [Abstract] [PDF]
|
|
|
|
|
|
H. H. Leuchte, M. Schwaiblmair, R. A. Baumgartner, C. F. Neurohr, T. Kolbe, and J. Behr Hemodynamic Response to Sildenafil, Nitric Oxide, and Iloprost in Primary Pulmonary Hypertension Chest, February 1, 2004; 125(2): 580 - 586. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. T. Schermuly, K. P. Kreisselmeier, H. A. Ghofrani, H. Yilmaz, G. Butrous, L. Ermert, M. Ermert, N. Weissmann, F. Rose, A. Guenther, et al. Chronic Sildenafil Treatment Inhibits Monocrotaline-induced Pulmonary Hypertension in Rats Am. J. Respir. Crit. Care Med., January 1, 2004; 169(1): 39 - 45. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Rosenkranz, F. Diet, T. Karasch, J. Weihrauch, K. Wassermann, and E. Erdmann Sildenafil Improved Pulmonary Hypertension and Peripheral Blood Flow in a Patient with Scleroderma-Associated Lung Fibrosis and the Raynaud Phenomenon Ann Intern Med, November 18, 2003; 139(10): 871 - 873. [Full Text] [PDF]
|
|
|
|
|
|
N. H. Kim, R. N. Channick, and L. J. Rubin Successful Withdrawal of Long-term Epoprostenol Therapy for Pulmonary Arterial Hypertension Chest, October 1, 2003; 124(4): 1612 - 1615. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. P. Cooke A Novel Mechanism for Pulmonary Arterial Hypertension? Circulation, September 23, 2003; 108(12): 1420 - 1421. [Full Text] [PDF]
|
|
|
|
 |
|
 W D Carroll and R Dhillon Sildenafil as a treatment for pulmonary hypertension Arch. Dis. Child., September 1, 2003; 88(9): 827 - 828. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Humbert, O. Sitbon, and G. Simonneau Novel therapeutic perspectives in pulmonary arterial hypertension Eur. Respir. J., August 1, 2003; 22(2): 193 - 194. [Full Text] [PDF]
|
|
|
|
|
|
H. A. Ghofrani, F. Rose, R. T. Schermuly, H. Olschewski, R. Wiedemann, A. Kreckel, N. Weissmann, S. Ghofrani, B. Enke, W. Seeger, et al. Oral sildenafil as long-term adjunct therapy to inhaled iloprost in severe pulmonary arterial hypertension J. Am. Coll. Cardiol., July 2, 2003; 42(1): 158 - 164. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Manganiello Cyclic Nucleotide Phosphodiesterase 5 and Sildenafil: Promises Realized Mol. Pharmacol., June 1, 2003; 63(6): 1209 - 1211. [Full Text] [PDF]
|
|
|
|
|
|
H. A. Ghofrani, R. T. Schermuly, F. Rose, R. Wiedemann, M. G. Kohstall, A. Kreckel, H. Olschewski, N. Weissmann, B. Enke, S. Ghofrani, et al. Sildenafil for Long-Term Treatment of Nonoperable Chronic Thromboembolic Pulmonary Hypertension Am. J. Respir. Crit. Care Med., April 15, 2003; 167(8): 1139 - 1141. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Article
